A bitter pill for Glaxo investors
PHARMACEUTICALS MATTHEW CURTIN OF DOW JONES NEWSWIRES
The Business
26 May 2007
IT’S been a terrible few days for GlaxoSmithKline, the British drugs giant. Investors have wiped more than £7bn off its market value because of fears over the safety of its Avandia group of diabetes drugs, one of the firm’s two blockbuster... read more...
PHARMACEUTICALS MATTHEW CURTIN OF DOW JONES NEWSWIRES
The Business
26 May 2007
IT’S been a terrible few days for GlaxoSmithKline, the British drugs giant. Investors have wiped more than £7bn off its market value because of fears over the safety of its Avandia group of diabetes drugs, one of the firm’s two blockbuster... read more...
0 Comments:
Post a Comment
<< Home